<p>Drug maker Sun Pharmaceutical Industries on Tuesday reported 23.32 per cent rise in fourth quarter consolidated net profit at Rs 1,011.56 crore and recommended a bonus issue of 1:1 to mark the completion of 30 years and crossing the $2 billion milestone in revenues.<br /><br /></p>.<p>The company's net profit was Rs 820.21 crore in the fourth quarter of 2011-12.<br /><br />Total income from operations stood at Rs 3,087.04 crore in Q4,FY2013, up 32.14 per cent from Rs 2,336.18 crore in Q4, FY2012. <br /><br />In a regulatory filing to the BSE, the company said that its board has recommended one bonus share for every share held to its shareholders and dividend of Rs 5 per share. <br /><br />The full year net profit for 2012-13 was Rs 3,008.06 crore, up 13.22 per cent from Rs 2,656.69 in 2011-12. Total income from operations in 2012-13 was Rs 11,299.86 crore as against Rs 8,019.75 crore in 2011-12. The company's stock closed at Rs 995.55 on the BSE, down 1.90 per cent from its previous close.</p>
<p>Drug maker Sun Pharmaceutical Industries on Tuesday reported 23.32 per cent rise in fourth quarter consolidated net profit at Rs 1,011.56 crore and recommended a bonus issue of 1:1 to mark the completion of 30 years and crossing the $2 billion milestone in revenues.<br /><br /></p>.<p>The company's net profit was Rs 820.21 crore in the fourth quarter of 2011-12.<br /><br />Total income from operations stood at Rs 3,087.04 crore in Q4,FY2013, up 32.14 per cent from Rs 2,336.18 crore in Q4, FY2012. <br /><br />In a regulatory filing to the BSE, the company said that its board has recommended one bonus share for every share held to its shareholders and dividend of Rs 5 per share. <br /><br />The full year net profit for 2012-13 was Rs 3,008.06 crore, up 13.22 per cent from Rs 2,656.69 in 2011-12. Total income from operations in 2012-13 was Rs 11,299.86 crore as against Rs 8,019.75 crore in 2011-12. The company's stock closed at Rs 995.55 on the BSE, down 1.90 per cent from its previous close.</p>